News

Published on 5 Feb 2022 on Benzinga via Yahoo Finance

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19


Article preview image

Cocrystal Pharma Inc (NASDAQ: COCP) has selected two investigational novel antiviral drug candidates for further development as oral treatments for COVID-19.

CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.Cocrystal plans to initiate a first-in-human trial with one selected candidate as soon as possible this year.Although CDI-988 and CDI-873 are chemically differentiated, both exhibited superior in vitro potency against SARS-CoV-2 with activity maintained against current variants of concern, including omicron.Related: Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant.Both candidates demonstrated a favorable safety profile and pharmacokinetic properties in preclinical studies supportive of daily oral dosing."In addition to initiating two COVID-19 trials in 2022, we anticipate completion of our influenza CC-42344 Phase 1 study this year," said James Martin, Cocrystal's CFO and interim co-CEO.Cocrystal received guidance from the FDA for further development of CDI-45205 in response to the Company's pre-Investigational New Drug (IND) briefing package.Price Action: COCP shares are up 0.56% at $0.51 during the market session on the last check Thursday.

NASDAQ.COCP price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
US Penny Stocks To Watch In December 2024

As the Federal Reserve's meeting on interest rates takes center stage, the U.S. markets are exper...

Simply Wall St. · via Yahoo Finance 17 Dec 2024

November 2024 US Exchange Standouts: Promising Penny Stocks

As the U.S. stock market navigates a "sometimes-bumpy path" toward its inflation target, as noted...

Simply Wall St. · via Yahoo Finance 15 Nov 2024

Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, Cocrystal Pharma, Inc. (COCP) could be a good stock pi...

Zacks · via Yahoo Finance 18 Jun 2024

Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A

Cocrystal Pharma Inc (NASDAQ: COCP) announced that CC-42344 demonstrated a favorable safety profi...

Benzinga via Yahoo Finance 17 Nov 2022

Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate

Cocrystal Pharma Inc (NASDAQ: COCP) selected CDI-988 for clinical development as an oral treatmen...

Benzinga via Yahoo Finance 11 Oct 2022

10 Biotech Penny Stocks with Growth Catalysts

In this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see som...

Insider Monkey via Yahoo Finance 6 Apr 2022

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344...

Benzinga via Yahoo Finance 27 Mar 2022

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Cocrystal Pharma Inc (NASDAQ: COCP) has selected two investigational novel antiviral drug candida...

Benzinga via Yahoo Finance 5 Feb 2022

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Cocrystal Pharma Inc's (NASDAQ: COCP) COVID-19 antiviral candidate has shown antiviral potency ag...

Benzinga via Yahoo Finance 28 Dec 2021

Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics

FinancialNewsMedia.com News Commentary - Acute Myeloid Leukemia (AML) is a type of blood cancer...

WFMZ Eastern Pennsylvania and Western New Jersey 15 Dec 2021